Enhancing Health and Care Worker Training to Foster Resilient Health Systems
We, the member countries of the Group of Friends of the WHO Academy, reaffirm our steadfast commitment to supporting the WHO Academy as a vital mechanism for enhancing the skills…
Lupin Digital Health Collaborates with Medicover Hospitals to Enhance Post-Discharge Cardiac Care
Lupin Digital Health, a wholly owned subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic collaboration with Medicover Hospitals to enhance cardiac care for patients in India.…
Lupin Acquires 3 Diabetes Trademarks from Boehringer Ingelheim
Lupin Limited, a leading global pharmaceutical company, has announced the acquisition of three key anti-diabetes trademarks—GIBTULIO®, GIBTULIO MET®, and AJADUO®—from Boehringer Ingelheim International GmbH. This strategic move is aimed at…
Neurocrine Announces FDA Approval of CRENESSITY for Congenital Adrenal Hyperplasia
Neurocrine Biosciences,has announced that the U.S. Food and Drug Administration (FDA) has approved CRENESSITY™ (crinecerfont) capsules and oral solution for use as an adjunctive treatment to glucocorticoid replacement in adults…
Acoramidis Granted Positive CHMP Opinion for Transthyretin Amyloid Cardiomyopathy Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending acoramidis for marketing authorization in the European Union (EU).…
Takeda Highlights Late-Stage Pipeline Advancing Transformative Treatments Across Multiple Areas
Takeda is hosting an investor R&D Day today, starting at 8:30 a.m. JST in Tokyo. The event will highlight the company’s late-stage pipeline, focusing on its transformative potential for patients…
FDA Grants Breakthrough Therapy Designation to Tolebrutinib for Non-Relapsing Secondary Progressive MS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This decision is based…
Lilly’s Omvoh Receives CHMP Recommendation for Crohn’s Disease Approval
Eli Lilly and Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Omvoh® (mirikizumab) for approval. Omvoh,…
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
AbbVie has announced a definitive agreement to acquire Nimble Therapeutics, a biotech company specializing in the discovery and development of innovative oral peptide therapies. This acquisition includes Nimble’s lead investigational…
Merck’s WELIREG Gains EU CHMP Backing for VHL Tumors and Advanced RCC
Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending…
Lynparza Shows Survival Benefit in Early Breast Cancer: OlympiA Trial
Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS),…
Pfizer’s IBRANCE Extends Progression-Free Survival in HR+, HER2+ Breast Cancer
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive…